ATXA THERAPEUTICS LTD -  

Ranking results:

Past rankings:

2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:500-600
Total Number of Projects:> 1000

Ranking timeline:

Project Participation Performance(2018-01-01 - 2025-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 2
As coordinator: 0
As participant: 0
Sole participant: 2
Coordinator / Participant Ratio: *

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2023 2.500.000 0 2.500.000 1
2018 2.499.000 0 2.499.000 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:

Constancy:

Total number of partners: 0
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 0
Frequent / Rare Partner Ratio: 0

Project overview:

Start dateProjectacronymrolefundingpartners
2023-01-01PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH). PAH-Advancecoordinator2.500.0001
2018-10-01New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH) PAH-HOPEcoordinator2.499.0001